Skip to main content

Optimal use of hospital resources and intervention using suPAR for improving prognosis and care for patients with COVID-19

Deliverables

Dissimination of results

ViroGates will use efforts to dissiminate the results obtained by the consortium. This can be through marketing material, video presentations, presentation at conferences, and through SoMe, e.g. Linkedin etc.

Study approval

Approval for the conduct of the trial by the first study site (M1)

Approval by ethical committee in countries where suPAR is not already routine

Approval by ethical committee and regulatory authorities in countries where suPAR is not already routine

Reporting of results

Statistical analysis of data: Writing of manuscripts. Publication in peer reviewed journals and presentations at conferences etc.

Registration and consent

HISS will finalize the protocol and the informed consent forms; EudraCT registration; drafting of contracts between investigators and hospital/university administration

Searching for OpenAIRE data...

Publications

Soluble Urokinase Receptor (SuPAR) in COVID-19–Related AKI

Author(s): Tariq U. Azam, Husam R. Shadid, Pennelope Blakely, Patrick O’Hayer, Hanna Berlin, Michael Pan, Peiyao Zhao, Lili Zhao, Subramaniam Pennathur, Rodica Pop-Busui, Izzet Altintas, Jens Tingleff, Marius A. Stauning, Ove Andersen, Maria-Evangelia Adami, Nicky Solomonidi, Maria Tsilika, Pinkus Tober-Lau, Eleni Arnaoutoglou, Verena Keitel, Frank Tacke, Athanasios Chalkias, Sven H. Loosen, Evangelos J. G
Published in: Journal of the American Society of Nephrology, Issue 31/11, 2020, Page(s) 2725-2735, ISSN 1046-6673
DOI: 10.1681/asn.2020060829